top of page

SPRAVATO® (esketamine) Treatment

We are now offering a new and innovative treatment with SPRAVATO® (esketamine).

    SPRAVATO® (esketamine), a nasal spray, is an FDA-approved treatment for

Treatment-Resistant Depression.

We are an official REMS-Certified Spravato® Clinic!

This is a very promising treatment for people who have suffered from moderate to severe depression for many years with previous ineffective trials of traditional psychotropic medications. SPRAVATO® (esketamine) is working very differently compared to traditional antidepressant medications


 As an NMDA (N-methyl D-aspartate) glutamate receptor antagonist it increases glutamate levels in the brain, which alleviates the symptoms of depression, enhances memory and the brain’s learning function.


Research shows that under chronic stress, the connection between neurons (brain cells) diminishes. Esketamine works on restoring those connections via growth-promoting effect as well as preventing the neurotoxic effects of depression.

Information about  SPRAVATO® (esketamine) Treatment

Please visit for more information.

If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression(TRD).

Medical Indications:

SPRAVATO® is a prescription medicine, used along with an antidepressant, taken by mouth to treat:

  • Adults with treatment-resistant depression (TRD)

  • Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® can cause serious side effects, including:

  • Sedation and dissociation. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation).

    • Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.

    • Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.

  • Abuse and misuse. There is a risk for abuse and physical and psychological dependence with SPRAVATO® treatment. Your healthcare provider should check you for signs of abuse and dependence before and during treatment with SPRAVATO®.

    • Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

    • Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.

  • SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.

  • Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed.

SPRAVATO® is not for use in children


Contraindications for  SPRAVATO® treatment:

  • have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)

  • have an abnormal connection between your veins and arteries (arteriovenous malformation)

  • have a history of bleeding in the brain

  • are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.

Administration of  SPRAVATO®

  • You will take SPRAVATO® nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.

  • Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.

  • Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.

  • During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.

  • You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.

  • If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.

  • Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.

  • If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.

Possible side effects of SPRAVATO®

SPRAVATO® may cause serious side effects including:

  • Increased blood pressure. 

  • Problems with thinking clearly.

  • Bladder problems.

The most common side effects of SPRAVATO® when used along with an antidepressant taken by mouth include:

  • feeling disconnected from yourself, your thoughts, feelings and things around you

  • dizziness

  • nausea

  • feeling sleepy

  • spinning sensation

  • decreased feeling of sensitivity (numbness)

  • feeling anxious

  • lack of energy

  • increased blood pressure

  • vomiting

  • feeling drunk

  • feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.

The information on this page was obtained from with permission.

  • Instagram
  • Facebook
bottom of page